2024 年至 2031 年重组蛋白市场规模（按产品类型、应用、最终用户和地区划分）

重组蛋白市场评估 - 2024-2031

受生物製药需求成长、蛋白质工程技术进步以及在治疗和诊断领域应用不断拓展的推动，重组蛋白市场正在经历显着成长。重组蛋白有望提供副作用较少的标靶治疗，从而刺激市场扩张。慢性病盛行率上升、蛋白质体学研究投入增加以及人工智慧在蛋白质设计和生产中的应用进一步推动了这一成长。预计这些因素将推动市场规模在2024年超过2.686亿美元，到2031年达到约5.3677亿美元。

除了这些成长要素外，研发投入也不断增加，旨在开发功能增强的新型重组蛋白。专注于改进蛋白质表现系统和扩大生产工艺，为市场扩张开闢了新的途径，尤其是在提高产量和成本效益方面。此外，新兴国家对重组蛋白的日益普及以及受託製造厂商的兴起，正在推动各地区市场的成长。对重组蛋白治疗和诊断产品日益增长的需求预计将推动市场在2024年至2031年间以9.04%的复合年增长率成长。

定义/摘要

重组蛋白是利用重组DNA技术生产的蛋白质。该技术涉及将编码特定蛋白质的基因插入宿主生物体，然后表达该蛋白质。重组蛋白因其高纯度、一致性和扩充性而被广泛应用于研究、诊断和治疗领域。该技术可以生产难以或无法从天然来源获得足够数量的蛋白质。

重组蛋白技术正在生命科学产业的各个领域开发和应用。在生物製药领域，它有助于开发针对各种疾病的标靶治疗。在研究应用中，它有助于研究蛋白质的功能和相互作用。在诊断领域，重组蛋白解决方案可以提高检测的特异性和灵敏度。

重组蛋白市场前景光明，新技术和新应用具有成长潜力。更先进的蛋白质工程技术的发展以及合成生物学方法的整合预计将带来新的市场机会。无细胞蛋白质合成技术的进步以及生产复杂多结构域蛋白质的可能性，或将带来更多样化和高效的重组蛋白产品。

生物製药需求的不断成长将如何推动重组蛋白市场的成长？

生物製药需求的不断成长是重组蛋白市场成长的主要驱动力。随着全球医疗保健系统转向使用生技药品治疗癌症、自体免疫疾病和遗传性疾病等慢性复杂疾病，高品质治疗性蛋白质的需求呈爆炸性增长。重组蛋白在这一趋势中发挥关键作用，它能够提供符合严格监管标准的、一致性、可扩展且高度特异性的蛋白质疗法。

重组技术能够生产多种蛋白质，包括单株抗体、生长因子、荷尔蒙和酶，这些对于创新药物和治疗方法的开发至关重要。这种多功能性使重组蛋白在治疗应用和研究环境中都至关重要，包括疫苗开发和细胞培养过程。此外，包括哺乳动物、细菌和酵母平台在内的表达系统的进步提高了生产效率、纯度和产量。对个人化医疗和标靶治疗的日益关注也促使製药和生物技术公司大力投资重组蛋白生产。这种趋势，加上研发活动的活性化和产业参与者之间的合作，正在刺激技术创新并扩大全球重组蛋白市场。

高生产成本的挑战如何影响重组蛋白市场的成长？

重组蛋白技术高的生产成本是影响重组蛋白市场成长的关键挑战。重组蛋白生产需要复杂的过程，包括细胞培养、蛋白质表现、纯化和品管，所有这些都需要专门的设备、熟练的人员和严格的法规遵循。这些因素增加了製造成本，使公司难以开发出负担得起的治疗方法，特别是在成本控制是优先事项的新兴市场。扩大商业用途的生产规模进一步增加了复杂性，因为在大规模生产中保持一致性、纯度和生物活性既具有挑战性又昂贵。这阻碍了重组蛋白治疗方法的广泛应用，特别是在医疗预算有限的地区。此外，降低全球医疗成本的压力正促使製药公司探索更有效率、永续的生产方法，包括製程优化、自动化和替代表达系统，如植物性和微生物平台。

目录

第一章全球重组蛋白市场简介

• 市场概况
• 调查范围
• 先决条件

第二章执行摘要

第三章：已验证的市场研究调查方法

• 资料探勘
• 验证
• 第一手资料
• 资料来源列表

第四章全球重组蛋白市场展望

• 概述
• 市场动态
  • 驱动程式
  • 阻碍因素
  • 机会
• 波特五力模型
• 价值链分析

5. 全球重组蛋白市场（依产品划分）

• 概述
• 免疫反应蛋白
• 结构蛋白
• 膜蛋白
• 激酶蛋白
• 调节蛋白
• 其他的

6. 全球重组蛋白市场（依应用）

• 概述
• 学术研究
• 生物技术调查
• 生物製药製造
• 药物发现与开发
• 其他的

7. 全球重组蛋白市场（依最终用户）

• 概述
• 受託研究机构
• 学术研究机构
• 生技公司
• 製药和生物製药公司
• 其他的

8. 全球重组蛋白市场（按地区）

• 概述
• 北美洲
  • 美国重组蛋白市场
  • 加拿大重组蛋白市场
• 欧洲
  • 德国重组蛋白市场
  • 英国重组蛋白市场
  • 法国重组蛋白市场
  • 义大利重组蛋白市场
  • 西班牙重组蛋白市场
• 亚太重组蛋白市场
  • 中国重组蛋白市场
  • 日本重组蛋白市场
  • 印度重组蛋白市场
  • 澳洲重组蛋白市场
  • 韩国蛋白质市场
• 世界其他地区
  • 拉丁美洲重组蛋白市场
  • 巴西重组蛋白市场
  • 阿根廷重组蛋白市场
• 中东和非洲重组蛋白市场
  • 阿联酋的重组蛋白市场

第九章：全球重组蛋白市场竞争格局

• 概述
• 各公司市场排名
• 主要发展策略

第十章：公司简介

• Aviva Systems Biology Corporation
• StressMarq Biosciences Inc.
• United States Biological
• ProteoGenix
• Icosagen AS
• Richcore Lifesciences Pvt Ltd.
• ProSpec-TechnoGene Ltd.
• ACROBiosystems
• CellGenix GmBH
• RayBiotech Inc.

第十一章 公司简介 附录

• 相关调查

Recombinant Proteins Market Valuation- 2024-2031

The Recombinant Proteins market is experiencing significant growth driven by increasing demand for biopharmaceuticals, advancements in protein engineering technologies, and rising applications in therapeutic and diagnostic fields. The potential for recombinant proteins to provide targeted therapies with fewer side effects continues to fuel market expansion. This growth is further bolstered by the rising prevalence of chronic diseases, increasing investment in proteomics research, and the integration of artificial intelligence in protein design and production. This is likely to enable the market size to surpass USD 268.6 Million valued in 2024 to reach a valuation of around USD 536.77 Million by 2031.

In addition to these growth factors, the market is witnessing increased investment in research and development aimed at developing novel recombinant proteins with enhanced functionalities. The focus on improving protein expression systems and scaling up production processes is opening new avenues for market expansion, particularly for enhanced yield and cost-effectiveness. Moreover, the growing adoption of recombinant proteins in emerging economies and the rise of contract manufacturing organizations are driving regional market growth. The rising demand for recombinant protein-based therapies and diagnostics is enabling the market to grow at a CAGR of 9.04% from 2024 to 2031.

Definition/Overview

Recombinant Proteins refer to proteins produced using recombinant DNA technology. This involves inserting a gene that codes for a specific protein into a host organism, which then expresses the protein. Recombinant proteins are widely used in research, diagnostics, and therapeutics due to their high purity, consistency, and scalability of production. This technology allows for the production of proteins that may be difficult or impossible to obtain from natural sources in sufficient quantities.

Recombinant protein technologies are being developed and utilized across various areas of the life sciences industry. In biopharmaceutical production, they help create targeted therapies for various diseases. For research applications, they assist in studying protein functions and interactions. In the realm of diagnostics, recombinant protein solutions enhance the specificity and sensitivity of tests.

The future scope of the Recombinant Proteins market is promising, with potential for growth in emerging technologies and applications. The development of more sophisticated protein engineering techniques and the integration of synthetic biology approaches are expected to open new market opportunities. Advancements in cell-free protein synthesis and the potential for producing complex multi-domain proteins may lead to more diverse and effective recombinant protein products.

How does the Increasing Demand for Biopharmaceuticals Drive the Growth of The Recombinant Proteins Market?

The increasing demand for biopharmaceuticals is a major driver of growth in the Recombinant Proteins Market. As healthcare systems worldwide shift toward biologics for the treatment of chronic and complex diseases, including cancer, autoimmune disorders, and genetic conditions, the need for high-quality therapeutic proteins has surged. Recombinant proteins play a crucial role in this trend by providing consistent, scalable, and highly specific protein-based therapeutics that meet stringent regulatory standards.

Recombinant technology enables the production of a wide variety of proteins, such as monoclonal antibodies, growth factors, hormones, and enzymes, which are essential for developing innovative drugs and therapies. This versatility makes recombinant proteins indispensable in both therapeutic applications and research settings, including vaccine development and cell culture processes. Additionally, advancements in expression systems, such as mammalian, bacterial, and yeast platforms, are enhancing production efficiency, purity, and yield. The increasing focus on personalized medicine and targeted therapies is also driving pharmaceutical and biotechnology companies to invest heavily in recombinant protein production. This trend, coupled with rising R&D activities and partnerships between industry players, is fostering innovation and expanding the global recombinant proteins market.

How is the Challenge of High Production Costs Impacting the Growth of The Recombinant Proteins Market?

The high production costs associated with recombinant protein technology are a significant challenge impacting the growth of the Recombinant Proteins Market. Producing recombinant proteins involves complex processes, such as cell culture, protein expression, purification, and quality control, all of which require specialized equipment, highly skilled personnel, and stringent regulatory compliance. These factors drive up manufacturing costs, making it difficult for companies to develop affordable therapies, particularly in markets where cost containment is a priority. Scaling up production for commercial use adds further complexity, as maintaining consistency, purity, and bioactivity at larger scales is both challenging and expensive. This poses barriers to the widespread adoption of recombinant protein-based therapies, especially in regions with limited healthcare budgets. Additionally, the pressure to reduce healthcare costs globally is pushing pharmaceutical companies to explore more efficient and sustainable production methods, such as process optimization, automation, or alternative expression systems like plant-based or microbial platforms.

Category-wise Acumens

How will the Adoption of Mammalian Expression Systems Drive the Growth of the Growth Factors Segment in Recombinant Proteins?

The adoption of mammalian expression systems is driving significant growth in the Growth Factors segment of the recombinant proteins market. Growth factors, such as erythropoietin, insulin-like growth factors, and granulocyte colony-stimulating factors (G-CSFs), are essential for a variety of therapeutic applications, including tissue regeneration, wound healing, and cancer treatment. As demand for these complex proteins increases, mammalian expression systems have become the preferred production platform due to their ability to perform critical post-translational modifications.

Mammalian systems, such as Chinese hamster ovary (CHO) cells, provide high biological similarity to native human proteins, ensuring improved efficacy and reducing the risk of immunogenic responses in patients. This alignment with therapeutic needs is enhancing interest in and development of recombinant growth factors produced using these systems. Additionally, advancements in cell line development, bioprocess optimization, and scalable bioreactors are improving production yields and cost-efficiency, further accelerating the adoption of mammalian platforms.

How will the Growth of Regenerative Medicine Drive the Expansion of The Research & Development Application Segment?

The growth of the Research & Development Application Segment will be driven by the rapid expansion of regenerative medicine. Factors such as the increasing focus on stem cell research, the need for novel tissue engineering approaches, and the desire for more effective regenerative therapies will contribute to this trend. Recombinant proteins for research and development will be sought to provide efficient and versatile tools for studying cellular processes, developing new therapies, and advancing regenerative medicine technologies.

Increased investment in recombinant protein research will be witnessed, enabling scientists to improve their understanding of cellular biology, develop new drug targets, and enhance regenerative medicine protocols. The research & development application segment will benefit from the integration of advanced protein engineering techniques and improved production technologies, allowing for the creation of more diverse and functional recombinant proteins for research purposes, which will ultimately propel market expansion.

Country/Region-wise Acumens

Will the Presence of Major Biopharmaceutical Companies Drive the Dominance of North America in The Recombinant Proteins Market?

The dominance of North America in the recombinant proteins market is largely driven by the presence of major biopharmaceutical companies and well-established research infrastructures. The United States and Canada are home to some of the world's largest biotechnology and pharmaceutical firms, which play a pivotal role in advancing protein engineering, production technologies, and therapeutic development. These companies not only drive innovation but also establish partnerships with research institutions, fostering a collaborative ecosystem that accelerates the adoption and commercialization of recombinant proteins. North America's strong focus on drug discovery, personalized medicine, and life sciences research further reinforces its leadership in the market. The region's early embrace of biotechnology, combined with substantial investment in R&D, has positioned it at the forefront of breakthroughs in recombinant protein production. Favorable regulatory frameworks and extensive healthcare spending also support the development and deployment of recombinant protein-based therapies, ensuring widespread availability and market growth.

Will the Rapid Growth of the Biotechnology Sector Drive the Expansion of The Recombinant Proteins Market in Asia-Pacific?

The rapid growth of the biotechnology sector is a key driver of the expansion of the Recombinant Proteins Market in Asia-Pacific. With some of the world's fastest-growing economies and a large share of the global population, the region is well-positioned to embrace innovative biotechnology solutions. Governments and private investors are increasingly investing in life sciences research to address evolving healthcare needs, including the rising prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders. This trend is generating significant demand for recombinant protein-based therapies, diagnostics, and research tools. Countries like China, India, and South Korea are witnessing substantial growth in their biotechnology industries, supported by favorable policies, expanding research infrastructure, and increasing R&D activities. The region's growing biopharmaceutical manufacturing capabilities further enable cost-effective production of recombinant proteins, attracting partnerships and investments from global pharmaceutical companies. This synergy between a booming biotechnology sector, rising healthcare demands, and a large consumer base is accelerating the adoption of recombinant protein technologies in both therapeutic and research applications.

Competitive Landscape

The recombinant proteins market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the recombinant proteins market include:

Thermo Fisher Scientific, Inc.

Merck KGaA

GenScript Biotech Corporation

Eli Lilly and Company

Abcam plc

Novo Nordisk A/S

Hoffmann-La Roche Ltd

Amgen Inc.

Novartis AG

Biogen Inc.

Latest Developments

In March 2024, Thermo Fisher Scientific, Inc. launched a new high-yield recombinant protein production platform, significantly improving the efficiency and cost-effectiveness of large-scale protein manufacturing.

In June 2024, Merck KGaA successfully implemented an AI-powered protein design platform, demonstrating enhanced capabilities in developing novel recombinant proteins with improved functionalities.

In April 2024, GenScript Biotech Corporation introduced a novel recombinant protein library for CRISPR-Cas9 applications, catering to the growing demand for gene editing tools in research and therapeutics.

In August 2024, Eli Lilly and Company secured a major contract to supply its innovative recombinant insulin analogs for a national diabetes management program in a large Asian country, marking a significant step towards more accessible and effective diabetes treatments.

Recombinant Proteins Market, by Category

Product Type:

Growth Factors

Hormones

Enzymes

Antibodies

Others (Cytokines, Coagulation Factors)

Application:

Biopharmaceutical Production

Research & Development

Diagnostics

Others (Industrial Enzymes, Agriculture)

End-User:

Pharmaceutical & Biotechnology Companies

Academic & Research Institutes

Contract Research Organizations (CROs)

Others (Diagnostic Laboratories, Food & Beverage Industry)

Region:

North America

Europe

Asia-Pacific

Latin America

Middle East and Africa

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL RECOMBINANT PROTEINS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL RECOMBINANT PROTEINS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL RECOMBINANT PROTEINS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Immune Response Proteins
• 5.3 Structural Proteins
• 5.4 Membrane Proteins
• 5.5 Kinase Proteins
• 5.6 Regulatory Proteins
• 5.7 Others

6 GLOBAL RECOMBINANT PROTEINS MARKET, BY APPLICATION

• 6.1 Overview
• 6.2 Academic Research Studies
• 6.3 Biotechnology Research
• 6.4 Biopharmaceutical Production
• 6.5 Drug Discovery & Development
• 6.6 Others

7 GLOBAL RECOMBINANT PROTEINS MARKET, BY END-USER

• 7.1 Overview
• 7.2 Contract Research Organizations
• 7.3 Academic Research Institutes
• 7.4 Biotechnology Companies
• 7.5 Pharmaceutical & Biopharmaceutical Companies
• 7.6 Others

8 GLOBAL RECOMBINANT PROTEINS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 United States Recombinant Proteins Market
  • 8.2.2 Canada Recombinant Proteins Market
• 8.3 Europe
  • 8.3.1 Germany Recombinant Proteins Market
  • 8.3.2 United Kingdom Recombinant Proteins Market
  • 8.3.3 France Recombinant Proteins Market
  • 8.3.4 Italy Recombinant Proteins Market
  • 8.3.4 Spain Recombinant Proteins Market
• 8.4 Asia Pacific Recombinant Proteins Market
  • 8.4.1 China Recombinant Proteins Market
  • 8.4.2 Japan Recombinant Proteins Market
  • 8.4.3 India Recombinant Proteins Market
  • 8.4.4 Australia Recombinant Proteins Market
  • 8.4.5 South Korea Proteins Market
• 8.5 Rest of the World
  • 8.5.1 Latin America Recombinant Proteins Market
  • 8.5.2 Brazil Recombinant Proteins Market
  • 8.5.3 Argentina Recombinant Proteins Market
• 8.6 Middle East And Africa Recombinant Proteins Market
  • 8.6.1 United Arab Emirates Recombinant Proteins Market

9 GLOBAL RECOMBINANT PROTEINS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Aviva Systems Biology Corporation
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 StressMarq Biosciences Inc.
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 United States Biological
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 ProteoGenix
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Icosagen AS
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Richcore Lifesciences Pvt Ltd.
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 ProSpec-TechnoGene Ltd.
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 ACROBiosystems
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 CellGenix GmBH
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 RayBiotech Inc.
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research